Background: Despite the prevalence and quality of life impact of diabetic foot ulcer (DFU), novel topical and oral therapy standard-of-care remain an important research priority. To date, the lack of available data has made it difficult to assess the efficacy of topical and capsular RM diabetes wound cure for DFUs. Case Presentation: We report the case of a 59-year-old Nigerian woman P2+0 with 2 living children, a known diabetes mellitus patient since 2006 and has been compliant with her antidiabetic medications, who presented with complaint of right foot ulcer. We also report the case of a 69-year-old Nigerian man that presented with DFU. The latter is a known diabetic and hypertensive diagnosed 15 years prior to presentation. For the first case, both topical and capsular RM wound cure were applied twice daily over an area of the ulcer for 8 weeks. For the second case, only RM diabetes wound cure capsule applied twice daily was received for 8 weeks. Efficacy was analysed by lesion measurements and photographs to determine overall response rate (ORR), and complete response (CR). All doses were well tolerated, and potentially efficacious. At 8 weeks across all dose levels, subjects achieved 100.0% ORR and 50.0% CR. Conclusion: Application of topical and ingestion of the oral capsule of RM diabetes wound cure appear safe and well tolerated with some reduction in lesion pain. Some greater levels of lesion stabilization was observed in the subjects, and this demonstrated great clinical benefit in foot ulcers. A randomized, placebo-controlled trial to confirm these findings is recommended.